Arbutus Biopharma Files Definitive Proxy Statement
Ticker: ABUS · Form: DEF 14A · Filed: 2024-04-10T00:00:00.000Z
Sentiment: neutral
Topics: proxy-statement, annual-meeting, corporate-governance
Related Tickers: ABUS
TL;DR
Arbutus Biopharma (ABUS) filed proxy docs for May 22 meeting. Vote your shares!
AI Summary
Arbutus Biopharma Corp. filed its definitive proxy statement on April 10, 2024, for its annual meeting on May 22, 2024. The company, formerly known as Tekmira Pharmaceuticals Corp., is seeking shareholder approval for matters related to its business operations and corporate governance. The filing indicates no fee was required for this submission.
Why It Matters
This filing provides shareholders with crucial information regarding upcoming votes, allowing them to make informed decisions about the company's future direction and leadership.
Risk Assessment
Risk Level: low — This is a routine proxy filing, providing information to shareholders for an upcoming meeting, and does not contain new material financial or operational risks.
Key Numbers
- DEF 14A — Filing Type (Definitive Proxy Statement)
Key Players & Entities
- Arbutus Biopharma Corp. (company) — Registrant
- Tekmira Pharmaceuticals Corp. (company) — Former company name
- 0001140361-24-019091.txt (document) — Filing identifier
- 20240410 (date) — Filing date
- 20240522 (date) — Meeting date
FAQ
What is the purpose of this DEF 14A filing?
The purpose of this DEF 14A filing is to provide shareholders with information for the annual meeting scheduled for May 22, 2024, and to solicit their votes on various corporate matters.
When was this filing submitted to the SEC?
This filing was submitted to the SEC on April 10, 2024.
What is the name of the company filing this document?
The name of the company filing this document is Arbutus Biopharma Corp.
Has the company undergone any name changes?
Yes, the company was formerly known as TEKMIRA PHARMACEUTICALS Corp, with name changes noted on June 7, 2011, and October 3, 2008.
Is there a filing fee associated with this proxy statement?
No, the filing indicates that no fee was required for this submission.
From the Filing
0001140361-24-019091.txt : 20240410 0001140361-24-019091.hdr.sgml : 20240410 20240410160548 ACCESSION NUMBER: 0001140361-24-019091 CONFORMED SUBMISSION TYPE: DEF 14A PUBLIC DOCUMENT COUNT: 6 CONFORMED PERIOD OF REPORT: 20240522 FILED AS OF DATE: 20240410 DATE AS OF CHANGE: 20240410 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Arbutus Biopharma Corp CENTRAL INDEX KEY: 0001447028 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 980597776 STATE OF INCORPORATION: A1 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: DEF 14A SEC ACT: 1934 Act SEC FILE NUMBER: 001-34949 FILM NUMBER: 24835793 BUSINESS ADDRESS: STREET 1: 701 VETERANS CIRCLE CITY: WARMINSTER STATE: PA ZIP: 18974 BUSINESS PHONE: 604-419-3200 MAIL ADDRESS: STREET 1: 701 VETERANS CIRCLE CITY: WARMINSTER STATE: PA ZIP: 18974 FORMER COMPANY: FORMER CONFORMED NAME: TEKMIRA PHARMACEUTICALS Corp DATE OF NAME CHANGE: 20110607 FORMER COMPANY: FORMER CONFORMED NAME: TEKMIRA PHARMACEUTICALS CORP DATE OF NAME CHANGE: 20081003 DEF 14A 1 ny20020406x1_def14.htm DEF 14A TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ ​ ​ Filed by a Party other than the Registrant   ☐ Check the appropriate box:   ☐ Preliminary Proxy Statement   ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy Statement   ☐ Definitive Additional Materials   ☐ Soliciting Material under §240.14a-12 ARBUTUS BIOPHARMA CORPORATION (Name of Registrant as Specified in its Charter)   (Name of Person(s) Filing Proxy Statement, if Other Than the Registrant) Payment of Filing Fee (Check all boxes that apply): ☒ ​ ​ No fee required   ☐ ​ ​ Fee paid previously with preliminary materials   ☐ ​ ​ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11 TABLE OF CONTENTS ARBUTUS BIOPHARMA CORPORATION 701 Veterans Circle Warminster, Pennsylvania 18974, United States (267) 469-0914 April 10, 2024 Dear Shareholder: You are cordially invited to attend Arbutus Biopharma Corporation’s 2024 Annual General and Special Meeting of Shareholders to be held on Wednesday, May 22, 2024 (the “Annual Meeting”). The Annual Meeting will begin at 10:00 a.m. (Eastern Daylight Time) and will be held solely by means of live audio webcast online at http://www.virtualshareholdermeeting.com/ABUS2024. The enclosed Notice and Management Proxy Circular and Proxy Statement describe the matters to be presented at the Annual Meeting. Whether or not you plan to virtually attend the Annual Meeting, please vote as soon as possible to ensure that your shares will be represented and voted at the Annual Meeting. Due to voting rules that may prevent your bank or broker from voting your uninstructed shares on a discretionary basis in the election of directors and other non-routine matters, it is important that you cast your vote. We look forward to seeing you at the Annual Meeting.   ​ ​ Sincerely,   ​ ​     ​ ​ Frank Torti, M.D.   ​ ​ Chairman of the Board of Directors IMPORTANT NOTICE REGARDING THE AVAILABILITY OF PROXY MATERIALS FOR THE ANNUAL GENERAL AND SPECIAL MEETING OF SHAREHOLDERS TO BE HELD VIRTUALLY VIA THE INTERNET ON MAY 22, 2024: The Company is making this Proxy Statement/Circular, a form of proxy card, and our Annual Report for the year ended December 31, 2023 available electronically via the Internet at www.ProxyVote.com and our website, www.arbutusbio.com. On or about April 10, 2024, we will mail to our Shareholders a Notice of